{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-26-000115","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2026-08-11T20:10:31+00:00","discovered_at":"2026-08-11T20:12:00.387415+00:00","generated_at":"2026-08-11T20:12:45.692876+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pliant Therapeutics Q2 2026 net loss narrows to $22.4M; FORTIFY enrollment ahead of schedule","bullets":["Q2 2026 net loss $22.4M vs $43.3M prior-year; R&D spend $16.7M vs $32.2M, G&A $7.1M vs $13.4M on bexotegrast termination and headcount cuts.","Cash, equivalents and short-term investments of $159.6M at June 30, 2026; expected to fund operations into second half of 2028.","FORTIFY Phase 1b trial of PLN-101095 enrolling ahead of schedule; up to 102 patients across 3 cohorts; interim data expected 2027.","Appointed Flavia Borellini, Ph.D. and Robert Iannone, M.D. (Jazz Pharmaceuticals EVP R&D/CMO) to Board of Directors.","AACR data: PLN-101095 monotherapy raised IFN-γ, CXCL9 and granzyme-B only in responders, signaling T-cell reactivation."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-26-000115","json":"https://secwatch.observer/filing/0001746473-26-000115.json","markdown":"https://secwatch.observer/filing/0001746473-26-000115.md","text":"https://secwatch.observer/filing/0001746473-26-000115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000115/0001746473-26-000115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000115/plrx-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:12:45.692876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}